CompletedPhase 4

Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart Surgery

South Korea79 participantsStarted 2013-06

Plain-language summary

The aim of this study is to investigate whether RIPC protects the heart against ischemia reperfusion injury on the concentrically hypertrophied myocardium

Who can participate

Age range20 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged ≥20 years with severe degenerative AS presenting concentric remodeling of the LV, who were scheduled for AVR Exclusion Criteria: * diabetes mellitus, * coronary stenosis ≥70%, * renal failure (serum creatinine \> 2.0 mg/dL), * upper arm peripheral vascular disease, * LV ejection fraction \<50%

What they're measuring

Serum levels of CK-MB and Tn-T

Timeframe: baseline

Serum levels of CK-MB and Tn-T

Timeframe: 12-hour after surgery

Serum levels of CK-MB and Tn-T

Timeframe: 24-hour after surgery

Trial details

NCT IDNCT01946087

SponsorYonsei University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-04

View on ClinicalTrials.gov More Patients With Elective Aortic Valve Replacement trials